Market Overview

13D Filing From Biotechnology Value Fund On Oncothyreon Reveals 19.8% Stake


Shares of Oncothyreon Inc (USA) (NASDAQ: ONTY), a small-cap biopharmaceutical company, spiked higher by 10 percent early Monday morning after Biotechnology Value Fund reported a 19.8 percent stake in the company in a 13-D filing.

Biotechnology Value Fund is a private investment partnership that specializes in "fundamentally-driven public biotechnology investments."

According to the 13-D filing, "BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 18,799,368 Shares beneficially owned by Partners, excluding 5,000,000 Shares issuable upon the exercise of certain Warrants, 7,500,000 Shares issuable upon the exercise of certain Series C Convertible Preferred Stock, 5,333,000 Shares issuable upon the exercise of certain Series B Convertible Preferred Stock and 2,500,000 Shares issuable upon the exercise of certain Series A Convertible Preferred Stock, representing percentage ownership of approximately 19.8 percent of the Shares outstanding."

Shares of Oncothyreon have gained more than 15 percent since the start of 2015, but have lost more than 30 percent over the past month.

Posted-In: Biotechnology Value FundBiotech News Small Cap Analysis Movers Trading Ideas General


Related Articles (ONTY)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

CACI International Awarded Multi-Million Contract From U.S. Army For Electronic Warfare

Why This Noted Analyst Is Expecting A 'Solid' Q4 Report Out Of Fitbit